Skip to main content

Table 1 TA concentration in vials over time

From: Therapeutic and pharmaco-biological, dose-ranging multicentre trial to determine the optimal dose of TRAnexamic acid to reduce blood loss in haemorrhagic CESarean delivery (TRACES): study protocol for a randomised, double-blind, placebo-controlled trial

Concentration of TA (mg/mL)

Day 0

Day 15

Day 30

Day 60

Day 90

6 months

9 months

1 year

Vials with TA 0.5 g/10 mL

46

[45–47]

45,67

[44–49]

50.33

[49–52]

51

[50–52]

47.33

[46–50]

57.33

[54–61]

54.66

[53–56]

51

[50–52]

Vials with TA 1 g/10 mL

96

[93–101]

103.67

[102–109]

106

[102–112]

102.33

[102–103]

97

[96–98]

109.75

[106–114]

101.33

[101–102]

99.33

[99–100]

  1. TA tranexamic acid